1. Home
  2. REE vs CTXR Comparison

REE vs CTXR Comparison

Compare REE & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REE Automotive Ltd.

REE

REE Automotive Ltd.

HOLD

Current Price

$0.75

Market Cap

21.7M

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.81

Market Cap

19.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REE
CTXR
Founded
2011
2007
Country
Israel
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7M
19.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REE
CTXR
Price
$0.75
$0.81
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$11.75
$6.00
AVG Volume (30 Days)
109.4K
480.0K
Earning Date
12-17-2025
12-23-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$183,000.00
N/A
Revenue This Year
$327.73
N/A
Revenue Next Year
$36,888.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.65
52 Week High
$10.24
$5.95

Technical Indicators

Market Signals
Indicator
REE
CTXR
Relative Strength Index (RSI) 49.49 31.30
Support Level $0.65 $1.01
Resistance Level $0.82 $1.09
Average True Range (ATR) 0.07 0.11
MACD 0.01 -0.02
Stochastic Oscillator 62.99 24.60

Price Performance

Historical Comparison
REE
CTXR

About REE REE Automotive Ltd.

REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: